Insider Buying: Pulse Biosciences (NASDAQ:PLSE) COO Buys $49,966.28 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky purchased 1,036 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was bought at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the purchase, the chief operating officer directly owned 1,036 shares in the company, valued at $49,966.28. This represents a ? increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Liane Rae Teplitsky also recently made the following trade(s):

• On Friday, August 28th, Liane Rae Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The shares were purchased at an average price of $48.35 per share, with a total value of $49,993.90.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock opened at $47.57 on Monday. The business has a 50 day simple moving average of $35.38 and a two-hundred day simple moving average of $27.02. The stock has a market capitalization of $3.29 billion, a P/E ratio of -40.31 and a beta of 1.61. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $50.90.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The firm had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. As a group, research analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on PLSE. Canaccord Genuity Group raised their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a report on Monday, August 10th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Needham & Company LLC assumed coverage on Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in shares of Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the period. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences in the second quarter valued at approximately $28,000. Alliancebernstein L.P. lifted its holdings in Pulse Biosciences by 6.7% in the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.